Importantly, both anti-PD-1 and anti-CTLA4 antibodies in combination with imatinib were also effective at prolonging the survival of CML mice, suggesting that immune checkpoint molecules are crucial for the protection of CML LSCs against T cell antitumor immunity. Here, CTLA4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.